News Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Continue Reading Previous Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™Next Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program Related Stories News Silver Hammer and Stroud Resources Announce Updated Mineral Resource Estimate for the Santo Domingo Silver-Gold Project, Mexico News Acceleware Ltd. Reports Second Quarter 2026 Financial and Operating Results News Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update News Theralase(R) Releases Q2 2026 Financial Statements News Ticket Fairy Launches the World’s First Event Ticketing Command Line Built for AI Agents News Mesmerise Launches Call-to-Sale Attribution System After Audit Finds Most Conversions Invisible to Standard Tracking
